title: Pyramidal cell responses to gamma-aminobutyric acid differ in type I and type II cortical dysplasia.
abstract: Abnormalities in the gamma-aminobutyric acid (GABA)-ergic system could be responsible for seizures in cortical dysplasia (CD). We examined responses of pyramidal neurons to exogenous application of GABA, as well as alterations of GABAergic interneuron number and size in pediatric epilepsy surgery patients with non-CD, type I CD, and type II CD pathologies. We used the dissociated cell preparation for electrophysiology along with immunohistochemistry to identify number and size of GABAergic cells. Pyramidal neurons from type I CD tissue showed increased EC(50) and faster kinetics compared with cells from non-CD and type II CD tissue. Cytomegalic pyramidal neurons showed increased GABA peak currents and decreased peak current densities, longer kinetics, and decreased sensitivity to zolpidem and zinc compared with normal pyramidal cells from non-CD and type I CD. There were fewer but larger glutamic acid decarboxylase (GAD)-containing cells in type II CD tissue with cytomegalic neurons compared with non-CD, type I CD, and type II CD without cytomegalic neurons. In addition, GABA transporters (VGAT and GAT-1) showed increased staining surrounding cytomegalic neurons in type II CD tissue. These results indicate that there are differences in GABA(A) receptor-mediated pyramidal cell responses in type I and type II CD. Alterations in zolpidem and zinc sensitivities also suggest that cytomegalic neurons have altered GABA(A) receptor subunit composition. These findings support the hypothesis that patients with type I and type II CD will respond differently to GABA-mediated antiepileptic drugs and that cytomegalic neurons have features similar to immature neurons with prolonged GABA(A) receptor open channel times.
authors.affiliation: Mental Retardation Research Center, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA 90095, USA. vandre@mednet.ucla.edu
authors.forename: Véronique M
authors.initials: VM
authors.lastname: André
authors.forename: Carlos
authors.initials: C
authors.lastname: Cepeda
authors.forename: Harry V
authors.initials: HV
authors.lastname: Vinters
authors.forename: My
authors.initials: M
authors.lastname: Huynh
authors.forename: Gary W
authors.initials: GW
authors.lastname: Mathern
authors.forename: Michael S
authors.initials: MS
authors.lastname: Levine
mesh_terms: D002478:Cells, Cultured; D002648:Child; D002675:Child, Preschool; D005260:Female; D005455:Fluorescent Antibody Technique; D018755:GABA Agonists / Q000494:pharmacology; D005968:Glutamate Decarboxylase / Q000378:metabolism; D006801:Humans; D007150:Immunohistochemistry; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D054220:Malformations of Cortical Development / Q000150:complications / Q000378:metabolism* / Q000503:physiopathology*; D018613:Microscopy, Confocal; D018408:Patch-Clamp Techniques; D017966:Pyramidal Cells / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism; D012640:Seizures / Q000209:etiology / Q000601:surgery; D005680:gamma-Aminobutyric Acid / Q000378:metabolism*
chemical_list: D018755:GABA Agonists; D011963:Receptors, GABA-A; D005680:gamma-Aminobutyric Acid; D005968:Glutamate Decarboxylase